Nutex Health Inc. Q4 FY2024 earnings call

Management Statement and Operational Highlights

• Financial Growth: Full year 2024 total revenue reached $479.9 million, up 94% from 2023. Adjusted EBITDA increased from $10.8 million in 2023 to $123.7 million in 2024. Net income went from a loss of $46 million in 2023 to $52 million in 2024.
• No Surprises Act (NSA) and Arbitration: Implemented arbitration process in July 2024, with 60%-70% of billable visits submitted to IDR/arbitration portal, achieving an ~80% win rate. Revenue per visit increased 150%-250% compared to initial payments.
• Hospital Expansions: Opened 4 new hospitals in 2024, with plans for 3 hospitals in 2025 (scheduled Q3/Q4) and further expansions in subsequent years.
• Cost Management: Total facility level operating costs increased, but as a percentage of revenue decreased. G&A expenses as a percentage of total revenue decreased.
• Technology and AI: Planning to expand technology with AI tools for faster check-ins, predictive staffing, note writing, and supply optimization to save costs and free up resources for patient care.

Segment Performance

• Hospital Division:
  • Full year 2024 total revenue was $479.9 million, up 94% from $247.6 million in 2023. Fourth quarter 2024 total revenue was $257.6 million, up 270% from $69.7 million in 2023.
  • Mature hospitals (open prior to December 31, 2021) saw revenue increase by 175.6% in the fourth quarter of 2024 compared to the same period in 2023.
  • Hospital division visits increased by 9.8% (4,063 visits) to 45,444 visits in the fourth quarter of 2024 versus 41,381 visits in the same period in 2023, with mature hospitals growing at 3.1% in Q4 2024.
• Population Health Division:
  • Q4 2024 revenue was $7.9 million, up ~11% from $7.1 million in the same period in 2023.
  • Full year 2024 revenue was $30.9 million, up 4.4% from $29.6 million in the same period in 2023.

Guidance

• Arbitration Process: Continue using arbitration as a tool to collect fair reimbursement, with plans to submit 60%-70% of billable visits to the IDR/arbitration portal going forward, assuming insurers don't negotiate fairly.
• Hospital Openings: Expect 3 hospitals to open in 2025 (Q3/Q4) and further expansions in 2026 and beyond.
• Mature Hospitals: Aim for single-digit ER volume growth year-over-year, while also growing other service lines through increased staffing and expertise to treat more patients and illnesses.

Risks

• No Surprises Act Implementation: Flawed implementation initially hit revenue per patient reimbursement, though arbitration has helped.
• Arbitration Process Costs: Arbitration is costly, labor-intensive, and time-consuming. The loser bears arbitration fees.
• Variability in Results: Future arbitration results may vary based on insurer response, visit volume, and acuity, affecting revenue projections.

Question and Answer

• Q: Bill Sutherland with The Benchmark Company on arbitration process outlook A: Tom Vo and Jon Bates state arbitration is a tool to collect fair rates, with 60%-70% of billable visits in the process, ~80% win rate, and it's a continuing process depending on insurer negotiation.
• Q: Carl Byrnes with Northland Capital Markets on revenue recognition and adjusted EBITDA A: Jon Bates explains revenue is recognized based on visit analysis, with arbitration results adjusting estimates over time. Adjusted EBITDA in Q4 2024 was influenced by arbitration, with a similar trend expected going forward.
• Q: Anthony Vendetti with Maxim Group on hospital openings and mature hospital growth A: Tom Vo and Josh DeTillio discuss 4 new hospitals opened in 2024, 3 planned for 2025, and mature hospitals aiming for single-digit ER volume growth with expanded service lines and staffing.
• Q: Gene Mannheimer with Freedom Capital Markets on arbitration revenue and variability A: Jon Bates explains arbitration revenue recognition spans Q3-Q4 2024, with ongoing evaluation of visit-by-visit reimbursement and variability based on insurer response.